gene_symbol,uniprotkb_ac,test_disease_use,test_trade_name,test_manufacturer,test_submission,test_is_a_panel,biomarker_id,biomarker_origin,ncit_biomarker,do_name,doid,histological_type,approved_indication,actual_use,specimen_type,platform_method,test_number_genes,test_adoption_evidence,test_trial_id,test_approval_status,pmid,test_study_design,clinical_significance,biomarker_drug,biomarker_description
BRAF,P15056,Melanoma Cancer,Roche cobas DNA Sample Preparation Kit_ COBAS 4800 BRAF V600 MUTATION TEST,Roche Molecular Systems_ Inc. (RMS),P110020,N,-,somatic mutation,B-Raf Proto-Oncogene_ Serine/Threonine Kinase Gene_ BRAF_ BRAF Gene_ BRAF gene,melanoma,1909,Melanoma_ NOS (8720),prognosis,prognostic,Paraffin block,C and E,1,clinical use,NCT01107418,PMA,22391147,RetObs,The cobas 4800 BRAF V600 Mutation Test is an in vitro diagnostic device intended for the qualitative detection of the BRAF V600E mutation in DNA extracted from formalin­ fixed_ paraffin-embedded human melanoma tissue.,Vemurafenib,The cobas 4800 BRAF V600 Mutation Test is a real-time PCR test on the cobas 4800 system_ and is intended to be used as an aid in selecting melanoma patients whose tumors carry the BRAF V600E mutation for treatment with vemurafenib.
BRAF,P15056,Melanoma Cancer,THXID-BRAF KIT,BioMerieux_ Inc.,P120014,N,-,somatic mutation,B-Raf Proto-Oncogene_ Serine/Threonine Kinase Gene_ BRAF_ BRAF Gene_ BRAF gene,melanoma,1909,Melanoma_ NOS (8720),prognosis,prognostic,Paraffin block,C and E,1,clinical use,NCT01153763,PMA,25037456,RetObs,The THxIDTM BRAF kit is an In Vitro Diagnostic device intended for the qualitative detection of the BRAF V600E and V600K mutations in DNA samples extracted from formalin-fixed paraffin-embedded (FFPE) human melanoma tissue.,Dabrafenib [Tafinlar] and Trametinib [MekinistTM],The THxIDTM BRAF kit is a real-time PCR test on the ABI 7500 Fast Dx system and is intended to be used as an aid in selecting melanoma patients whose tumors carry the BRAF V600E mutation for treatment with dabrafenib [Tafinlar®] and as an aid in selecting melanoma patients whose tumors carry the BRAF V600E or V600K mutation for treatment with trametinib [MekinistTM].